Diagnosis challenges in a uterine leiomyosarcoma

Uterine leiomyosarcoma (LMS) represents a rare tumor, accounting for 1.3% of all uterine malignancies. Although this tumor shares morphological and clinical features with other uterine benign and malignant tumors, the accurate diagnosis is necessary, due to their different biological behavior and prognosis. Therefore, we present a case of LMS in a 48 year-old patient, complaining of a 3-months metrorrhagia. The tumor presented as a poorly defined submucosal nodule, with a soft consistence and measuring 6 cm in diameter. The microscopic examination of this tumor nodule revealed fascicles of spindle cells, with pleomorphic hyperchromatic nuclei exhibiting moderate to severe atypia and areas of tumor necrosis. At least 5 atypical mitoses/ 10 HPF were also found. Immunohistochemistry technique, with a panel of six antibodies, comprising ER, PR, PCNA, SMA, p53, and bcl-2, has been performed for the differential diagnosis. The final histopathological diagnosis was that of uterine LMS. Considering LMS an aggressive tumor, the patient has been recommended a thorough follow-up.

[1]  I. Kahramanoglu,et al.  Giant leiomyosarcoma: A case report , 2015, International journal of surgery case reports.

[2]  S. George,et al.  Uterine Sarcomas: Then and Now , 2012 .

[3]  R. Aggarwal,et al.  Epithelioid leiomyosarcoma of uterus , 2012, BMJ Case Reports.

[4]  A. Tinelli.  Uterine leiomyosarcomas and leiomyomas: Two similar uterine solid tumors, totally different for prognosis , 2011 .

[5]  Camille Stephan-Otto Attolini,et al.  Tumorigenesis and Neoplastic Progression A Differentiation-Based MicroRNA Signature Identifies Leiomyosarcoma as a Mesenchymal Stem Cell-Related Malignancy , 2010 .

[6]  G. Israel,et al.  MRI appearance of mesenchymal tumors of the uterus. , 2010, European journal of radiology.

[7]  A. Gadducci,et al.  The management of patients with uterine sarcoma: a debated clinical challenge. , 2008, Critical reviews in oncology/hematology.

[8]  H. Yoshikawa,et al.  Smooth muscle tumors of uncertain malignant potential and leiomyosarcomas of the uterus: MR findings , 2004, Journal of magnetic resonance imaging : JMRI.

[9]  J. Goldblum,et al.  Estrogen and Progesterone Receptor Expression in Uterine and Extrauterine Leiomyosarcomas: An Immunohistochemical Study , 2004, Applied immunohistochemistry & molecular morphology : AIMM.

[10]  O. Kimberger,et al.  Bcl-2 Receptor Expression in Patients With Uterine Smooth Muscle Tumors: An Immunohistochemical Analysis Comparing Leiomyoma, Uterine Smooth Muscle Tumor of Uncertain Malignant Potential, and Leiomyosarcoma , 2004, Journal of the Society for Gynecologic Investigation.

[11]  H. Yoshida.  Apoptotic Cell Death and p53 Expression in Leiomyosarcoma of Soft-Tissue Origin , 2001 .

[12]  N. Umesaki,et al.  Positron emission tomography with (18)F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power Doppler imaging. , 2001, Gynecologic oncology.

[13]  E. Outwater,et al.  Uterine leiomyomas: histopathologic features, MR imaging findings, differential diagnosis, and treatment. , 1999, Radiographics : a review publication of the Radiological Society of North America, Inc.

[14]  E. Oliva,et al.  Tumours of the uterine corpus: Mesenchymal tumours , 2014 .

[15]  J. Prat,et al.  Uterine sarcomas: a review. , 2010, Gynecologic Oncology.

[16]  A. Adesiyun,et al.  Leiomyosarcoma uteri in a white woman. , 2010, Annals of African medicine.

[17]  E. Oliva.  Chapter 8 – Pure Mesenchymal and Mixed Müllerian Tumors of the Uterus , 2009 .

[18]  S. Leodolter,et al.  Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters. , 2003, Anticancer research.

[19]  C. Zaloudek,et al.  Mesenchymal Tumors of the Uterus , 1987 .